Document Detail

Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin.
MedLine Citation:
PMID:  8352539     Owner:  NLM     Status:  MEDLINE    
Exponentially growing Molt-4 cells were separated by means of counterflow centrifugation into fractions enriched for cells in early G1, late G1, S, or G2+M phase of the cell cycle. Subsequently, cells were exposed for 2 h to Idarubicin (Ida, 0.02-0.15 microgram/ml). Daunorubicin (Dnr, 0.1-0.75 microgram/ml) or Doxorubicin (Dox, 0.1-0.75 microgram/ml). Drug uptake, measured by flow cytometry, increased progressively with cell cycle traverse from early G1-to M-phase. The relative fraction of drug lost following an extensive wash procedure was 72% in case of Ida and 23% for Dnr and Dox and was independent of the cell cycle phase. Inhibition of DNA synthesis was determined by qualitative flow cytometric analysis of 5-iodo-2'-deoxyuridine (IdUrd) incorporation into DNA. The three drugs showed a similar gradual increase of inhibition of DNA synthesis from G1 to G2+M phase, demonstrating that cell cycle phase dependency of drug toxicity applies to all three anthracyclines studied.
H Minderman; P Linssen; J Wessels; C Haanen
Related Documents :
1695009 - Cell cycle synchronization: reversible induction of g2 synchrony in cultured rodent and...
12464389 - Growth/differentiation factor-5 induces growth arrest and apoptosis in mouse b lineage ...
18300019 - Effect of neutron capture therapy on the cell cycle of human squamous cell carcinoma ce...
11156939 - Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts.
6170499 - Proliferation kinetics of perturbed cell populations determined by the bromodeoxyuridin...
2634429 - Cytotoxicity by tumor necrosis factor is linked with the cell cycle but does not requir...
7865989 - Metal loading and enzymatic degradation of fungal cell walls and chitin.
24153299 - Chromatin dynamics during cellular reprogramming.
9448099 - Anti-proliferative effect of toremifene and tamoxifen on estrogen receptor-lacking anap...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  13     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    1993 Jul-Aug
Date Detail:
Created Date:  1993-09-14     Completed Date:  1993-09-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  GREECE    
Other Details:
Languages:  eng     Pagination:  1161-5     Citation Subset:  IM    
Department of Hematology, University Hospital Nijmegen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Transport
Cell Cycle*
Daunorubicin / metabolism*,  toxicity
Doxorubicin / metabolism*,  toxicity
G1 Phase
G2 Phase
Idarubicin / metabolism*,  toxicity
Leukemia-Lymphoma, Adult T-Cell
S Phase
Tumor Cells, Cultured
Reg. No./Substance:
20830-81-3/Daunorubicin; 23214-92-8/Doxorubicin; 58957-92-9/Idarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hypercalcemia of cancer: an update.
Next Document:  C-myc expression is down-regulated in mafosfamide-treated HL-60 cells undergoing apoptosis.